CTLA4 and neoplasm: Therefore, many preclinical studies have been conducted on the synergistic effects between RT and immunotherapy using immune checkpoint inhibitors, which suggest that the anti-tumor effects of RT are further enhanced by the concurrent administration of antibodies to CTLA-4 and PD-128–30.